Literature DB >> 19941974

The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolism.

Neil A Goldenberg1, Mark Tripputi, Mark Crowther, Thomas C Abshire, Donna DiMichele, Marilyn J Manco-Johnson, William R Hiatt.   

Abstract

In traditional randomized controlled trial (RCT) designs, patients who are ineligible for randomization are excluded from study participation. However, these patients often constitute an important subgroup of the disease population. By extending existing RCT infrastructure, efforts to evaluate such patients in parallel cohort arms would provide an efficient means of generating multi-center prospective data on natural history, which would facilitate the development of future RCTs involving these subgroups of interest. This brief report discusses principles of the parallel-cohort RCT design, describes the few published trials in which it has been employed, and highlights novel aspects of its use in the Kids-DOTT trial-an ongoing multi-center randomized trial of the duration of anticoagulant therapy for venous thrombosis in children. Copyright (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19941974     DOI: 10.1016/j.cct.2009.11.006

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  7 in total

1.  In Children with Provoked Venous Thromboembolism, Increasing Plasma Coagulability during the First 3 Months Postdiagnosis is Prognostic of Recurrence.

Authors:  Marisol Betensky; M Gail Mueller; Ernest K Amankwah; Neil A Goldenberg
Journal:  Thromb Haemost       Date:  2020-05-05       Impact factor: 5.249

Review 2.  Current and future management of pediatric venous thromboembolism.

Authors:  Bryce A Kerlin
Journal:  Am J Hematol       Date:  2012-02-24       Impact factor: 10.047

3.  Plasma fibrinolysis, inflammatory markers, and postthrombotic syndrome: preliminary findings from the Kids-DOTT Biobank.

Authors:  Marisol Betensky; Ernest K Amankwah; Stephanie Brandal; Allen D Everett; Neil A Goldenberg
Journal:  Blood Adv       Date:  2021-01-12

4.  Multicenter randomized controlled trial on Duration of Therapy for Thrombosis in Children and Young Adults (the Kids-DOTT trial): pilot/feasibility phase findings.

Authors:  N A Goldenberg; T Abshire; P J Blatchford; L Z Fenton; J L Halperin; W R Hiatt; C M Kessler; J M Kittelson; M J Manco-Johnson; A C Spyropoulos; P G Steg; N V Stence; A G G Turpie; S Schulman
Journal:  J Thromb Haemost       Date:  2015-08-11       Impact factor: 5.824

5.  Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism: The Kids-DOTT Randomized Clinical Trial.

Authors:  Neil A Goldenberg; John M Kittelson; Thomas C Abshire; Marc Bonaca; James F Casella; Rita A Dale; Jonathan L Halperin; Frances Hamblin; Craig M Kessler; Marilyn J Manco-Johnson; Robert F Sidonio; Alex C Spyropoulos; P Gabriel Steg; Alexander G G Turpie; Sam Schulman
Journal:  JAMA       Date:  2022-01-11       Impact factor: 157.335

Review 6.  Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach.

Authors:  J M Kittelson; A C Spyropoulos; J L Halperin; C M Kessler; S Schulman; G Steg; A G G Turpie; N R Cutler; W R Hiatt; N A Goldenberg
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

7.  Participation in a clinical trial of a text messaging intervention is associated with increased infant HIV testing: A parallel-cohort randomized controlled trial.

Authors:  Thomas A Odeny; Elizabeth A Bukusi; Elvin H Geng; James P Hughes; King K Holmes; R Scott McClelland
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.